PMID- 35702098
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Electronic)
IS  - 1943-8141 (Linking)
VI  - 14
IP  - 5
DP  - 2022
TI  - Correlation between salivary HBD-2 and LL-37 expression levels with blood glucose 
      and periodontal status in patients with type 2 diabetes mellitus.
PG  - 3286-3291
AB  - OBJECTIVE: To examine the correlation between salivary human beta defensin-2 (HBD-2) 
      and LL-37 expression levels and blood glucose in relationship to periodontal 
      status in patients with type 2 diabetes mellitus (T2DM). METHODS: The trial is 
      available at: https://clinicaltrials.gov/ with ClinicalTrials.gov Identifier: 
      NCT03512675. A total of 89 patients with T2DM with chronic periodontitis (CP) 
      enrolled in our hospital from January 2020 to December 2020 were selected. 
      According to the degree of glycemic control and CP, the patients were randomly 
      divided into four groups, namely the good glycemic control and mild CP group 
      (n=26), good glycemic control with moderate to severe CP group (n=24), poor 
      glycemic control with mild CP group (n=21), and poor glycemic control with 
      moderate to severe CP group (n=18). The periodontal clinical parameters, blood 
      glucose indicators, and saliva HBD-2 and LL-37 expression levels were determined. 
      RESULTS: The expression levels of HBD-2 and LL-37 in the saliva of T2DM patients 
      with moderate to severe CP and poor blood sugar control were significantly 
      increased (P<0.05). Saliva HBD-2 and LL-37 levels were positively correlated with 
      probing depth, clinical attachment loss, plaque index, and glycosylated 
      hemoglobin. There was a synergistic interaction between blood glucose, 
      periodontal status, and saliva HBD-2, LL-37 levels (P<0.05). CONCLUSION: There is 
      a positively correlated relationship between blood glucose and periodontal status 
      with salivary HBD-2 and LL-37 levels.
CI  - AJTR Copyright (c) 2022.
FAU - Xiao, Zunsheng
AU  - Xiao Z
AD  - Department of Stomatology, Cangzhou Central Hospital Hebei, China.
FAU - Ding, Wencui
AU  - Ding W
AD  - The First Department of Endocrine Diabetes, Cangzhou Central Hospital Cangzhou, 
      Hebei, China.
FAU - Wen, Chao
AU  - Wen C
AD  - Department of Clinical Laboratory, Cangzhou Central Hospital Hebei, China.
FAU - Ge, Chao
AU  - Ge C
AD  - Department of Stomatology, Cangzhou Central Hospital Hebei, China.
FAU - Liu, Lu
AU  - Liu L
AD  - Department of Stomatology, Cangzhou Central Hospital Hebei, China.
FAU - Xu, Ke
AU  - Xu K
AD  - Department of Stomatology, Cangzhou Central Hospital Hebei, China.
FAU - Cao, Sumin
AU  - Cao S
AD  - Department of Stomatology, Cangzhou Central Hospital Hebei, China.
LA  - eng
PT  - Journal Article
DEP - 20220515
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC9185056
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - antimicrobial peptide-37
OT  - human beta defensin-2
OT  - periodontitis
COIS- None.
EDAT- 2022/06/16 06:00
MHDA- 2022/06/16 06:01
PMCR- 2022/05/15
CRDT- 2022/06/15 02:03
PHST- 2021/06/20 00:00 [received]
PHST- 2022/02/07 00:00 [accepted]
PHST- 2022/06/15 02:03 [entrez]
PHST- 2022/06/16 06:00 [pubmed]
PHST- 2022/06/16 06:01 [medline]
PHST- 2022/05/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Transl Res. 2022 May 15;14(5):3286-3291. eCollection 2022.